Access count of this item: 1078

Files in This Item:
File Description SizeFormat 
57_177.pdf1.61 MBAdobe PDFView/Open
Title: 酢酸クロルマジノン投与による前立腺肥大症患者の血清PSA値およびテストステロン値の変動 - 多施設共同前向き臨床研究
Other Titles: Changes in Serum Prostate Specific Antigen and Testosterone Levels after Chlormadinone Acetate Treatment in Patients with Benign Prostatic Hyperplasia : A Prospective Multicenter Clinical Study
Authors: 藤本, 清秀  KAKEN_name
平尾, 佳彦  KAKEN_name
大橋, 靖雄  KAKEN_name
柴田, 康博  KAKEN_name
冨士, 幸蔵  KAKEN_name
辻, 秀憲  KAKEN_name
清水, 信貴  KAKEN_name
宮澤, 克人  KAKEN_name
永田, 仁夫  KAKEN_name
大谷, 幹伸  KAKEN_name
古屋, 亮兒  KAKEN_name
朴, 英哲  KAKEN_name
Author's alias: Fujimoto, Kiyohide
Hirao, Yoshihiko
Ohashi, Yasuo
Shibata, Yasuhiro
Fuji, Kohzo
Tsuji, Hidenori
Shimizu, Nobutaka
Miyazawa, Katsuhito
Nagata, Masao
Ohtani, Nikinobu
Furuya, Ryoji
Boku, Eitetsu
Keywords: Benign prostatic hyperplasia
chlormadinone acetate
prostate specific antigen
testosterone
prospective multicenter study
Issue Date: Apr-2011
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 57
Issue: 4
Start page: 177
End page: 183
Abstract: In this prospective multicenter study, we investigated the changes in serum prostate-specific antigen (PSA) and testosterone levels after treatment with antiandrogen chlormadinone acetate (CMA) in patients with benign prostatic hyperplasia (BPH). The inclusion criteria for the patients were as follows : PSA value of C10 ng/ml, maximum urine flow rate of <15 ml/s, estimated prostate volume of B20 ml, International Prostate System Score (IPSS) of B8, and IPSS-quality of life (QOL) index of B2. Of the 115 patients who registered, 114 qualified for this study. The patients were treated with CMA (50 mg/day) for 16 weeks ; this was followed by a no-CMA phase of 32 weeks. When compared with the baseline PSA level, the levels at 8 and 16 weeks of treatment had decreased by 56.4% (95% confidence interval [CI], 51.1-1.2) and 57.6% (95% CI, 52.3-62.4), respectively. Similarly, when compared with the baseline testosterone level, the levels at 8 and 16 weeks of treatment had decreased by 90.1% (95% CI, 87.8-91.9) and 84.4% (95% CI, 80.7-87.4), respectively. After treatment discontinuation, the PSA levels gradually increased and returned to baseline in 32 weeks. However, the testosterone levels returned to baseline in only 8 weeks. Although patients over 80 years of age showed a gradual decrease in these levels when compared with younger patients, the changes in the levels of PSA and testosterone were not affected by age. Thus, in order to use antiandrogen agents including CMA for treating BPH, we need to determine the PSA value that converted it into double.
Rights: 許諾条件により本文は2012-05-01に公開
URI: http://hdl.handle.net/2433/141827
PubMed ID: 21646847
Appears in Collections:Vol.57 No.4

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.